EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cabaletta Bio's Enterprise Value is $-74.43 Mil.
Cabaletta Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-83.57 Mil. Therefore, Cabaletta Bio's EV-to-FCF for today is 0.89.
The historical rank and industry rank for Cabaletta Bio's EV-to-FCF or its related term are showing as below:
CABA'
s EV-to-FCF Range Over the Past 10 Years
Min: -18.53 Med: 0 Max: 2.36
Current: 0.89
During the past 7 years, the highest EV-to-FCF of Cabaletta Bio was 2.36. The lowest was -18.53. And the median was 0.00.
CABA's EV-to-FCF is ranked better than 63.29% of 425
companies
in the Biotechnology industry
Industry Median: 3.51
vs CABA: 0.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Cabaletta Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cabaletta Bio's EV-to-FCF
For the Biotechnology subindustry, Cabaletta Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's EV-to-FCF falls into.
Cabaletta Bio EV-to-FCF Calculation
Cabaletta Bio's EV-to-FCF for today is calculated as:
Cabaletta Bio's current Enterprise Value is $-74.43 Mil.
Cabaletta Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-83.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio (NAS:CABA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cabaletta Bio's PE Ratio (TTM) for today is calculated as:
Cabaletta Bio's share price for today is $1.78.
Cabaletta Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cabaletta Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cabaletta Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CABA has been successfully added to your 